ArticleFrontiers in medicine2026
Serum magnesium is associated with osteoporosis risk in postmenopausal women: a retrospective study and risk-prediction model.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between serum magnesium (Mg) levels and osteoporosis (OP)/osteoporotic fractures in postmenopausal women, and to develop a multi-parameter model for predicting OP risk. Methods: This retrospective study included 496 hospitalized postmenopausal women from January 1, 2021 to June 30, 2025. Patients were categorized into the OP group (T-score ≤ -2.5) and the non-OP group ( Results: Among 496 participants, 208 were classified as non-OP and 288 as OP. Osteoporotic fractures were identified in 31 patients, while 465 had no osteoporotic fractures. patients with OP were older, had lower body mass index (BMI), lower BMD, and lower serum Mg and P levels. ROC analysis showed modest discrimination for Mg (AUC 0.602, 95% CI 0.551-0.652), with an optimal cut-off of 0.845 mmol/L. After adjustment for potential confounders, Mg ≤ 0.845 mmol/L was independently associated with higher odds of OP (OR 1.940, 95% CI 1.312-2.868; Conclusion: Lower serum Mg levels were associated with OP and osteoporotic fractures in hospitalized postmenopausal women. Mg may support OP risk stratification, and a multi-parameter model integrating clinical and bone metabolism-related markers may further improve risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.